AustralieFrV1, PubMed, Checkpoint, bibRecord, 000D42

Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.

Identifieur interne : 000D42 ( PubMed/Checkpoint ); précédent : 000D41; suivant : 000D43

Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.

Auteurs : Christophe Hézode [France] ; Massimo Colombo [Italie] ; Marc Bourlière [France] ; Ulrich Spengler [Allemagne] ; Ziv Ben-Ari [Israël] ; Simone I. Strasser [Australie] ; William M. Lee [États-Unis] ; Leslie Morgan [États-Unis] ; Jingjun Qiu [États-Unis] ; Peggy Hwang [États-Unis] ; Michael Robertson [États-Unis] ; Bach-Yen Nguyen [États-Unis] ; Eliav Barr [États-Unis] ; Janice Wahl [États-Unis] ; Barbara Haber [États-Unis] ; Robert Chase [États-Unis] ; Rohit Talwani [États-Unis] ; Vito Di Marco [Italie]

Source :

Hepatology (Baltimore, Md.) [ 1527-3350 ] ; 2017.

RBID : pubmed:28256747

Descripteurs français

English descriptors

KwdEn :
- Administration, Oral, Adult, Benzofurans (administration & dosage), Biopsy, Needle, Blood Coagulation Disorders, Inherited (complications), Blood Coagulation Disorders, Inherited (diagnosis), Blood Coagulation Disorders, Inherited (drug therapy), Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Hepacivirus (drug effects), Hepatitis C, Chronic (complications), Hepatitis C, Chronic (diagnosis), Hepatitis C, Chronic (drug therapy), Humans, Imidazoles (administration & dosage), Immunohistochemistry, Liver Function Tests, Male, Middle Aged, Quinoxalines (administration & dosage), Reference Values, Severity of Illness Index, Treatment Outcome.
MESH :
- chemical , administration & dosage : Benzofurans, Imidazoles, Quinoxalines.
- complications : Blood Coagulation Disorders, Inherited, Hepatitis C, Chronic.
- diagnosis : Blood Coagulation Disorders, Inherited, Hepatitis C, Chronic.
- drug effects : Hepacivirus.
- drug therapy : Blood Coagulation Disorders, Inherited, Hepatitis C, Chronic.
- Administration, Oral, Adult, Biopsy, Needle, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Immunohistochemistry, Liver Function Tests, Male, Middle Aged, Reference Values, Severity of Illness Index, Treatment Outcome.

Abstract

Direct-acting antiviral agents have not been studied exclusively in patients with inherited blood disorders and hepatitis C virus (HCV) infection. The objective of the randomized, placebo-controlled, phase III C-EDGE IBLD study was to assess the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) in patients with inherited bleeding disorders and HCV infection. One hundred fifty-nine adults with HCV infection and sickle cell anemia, thalassemia, or hemophilia A/B or von Willebrand disease were enrolled at 31 study sites in the United States, Europe, Australia, Canada, Israel, and Thailand. Patients were given an oral, once-daily, fixed-dose combination of EBR/GZR 50 mg/100 mg for 12 weeks and randomized to the immediate-treatment group (ITG) or deferred-treatment group (DTG; placebo followed by active treatment). The primary endpoints were the proportion of patients in the ITG with unquantifiable HCV RNA 12 weeks posttreatment (sustained virological response 12 weeks after completion of study treatment; SVR12) and the comparison of safety in the ITG and DTG. In the ITG, 100 of 107 patients (93.5%) achieved SVR12, 6 relapsed, and 1 was lost to follow-up. SVR12 was achieved in 94.7% (18 of 19), 97.6% (40 of 41), and 89.4% (42 of 47) of patients with sickle cell disease, β-thalassemia, and hemophilia A/B or von Willebrand disease, respectively. Serious adverse events were reported by 2.8% (n = 3) and 11.5% (n = 6) of patients in the ITG and DTG, respectively. Hemoglobin levels and international normalized ratio values were similar in patients receiving EBR/GZR and placebo; among patients with hemoglobinopathies, change in mean hemoglobin levels was similar in those receiving EBR/GZR compared to those receiving placebo.

DOI: 10.1002/hep.29139
PubMed: 28256747

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000665
to stream PubMed, to step Curation: 000663

Links to Exploration step

pubmed:28256747

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.</title>
<author><name sortKey="Hezode, Christophe" sort="Hezode, Christophe" uniqKey="Hezode C" first="Christophe" last="Hézode">Christophe Hézode</name>
<affiliation wicri:level="3"><nlm:affiliation>Henri Mondor Hospital, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Henri Mondor Hospital, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Colombo, Massimo" sort="Colombo, Massimo" uniqKey="Colombo M" first="Massimo" last="Colombo">Massimo Colombo</name>
<affiliation wicri:level="1"><nlm:affiliation>Humanitas Clinical and Research Center, Rozzano, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Humanitas Clinical and Research Center, Rozzano</wicri:regionArea>
<wicri:noRegion>Rozzano</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bourliere, Marc" sort="Bourliere, Marc" uniqKey="Bourliere M" first="Marc" last="Bourlière">Marc Bourlière</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint Joseph, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Saint Joseph, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Spengler, Ulrich" sort="Spengler, Ulrich" uniqKey="Spengler U" first="Ulrich" last="Spengler">Ulrich Spengler</name>
<affiliation wicri:level="3"><nlm:affiliation>University Hospital Bonn, Bonn, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>University Hospital Bonn, Bonn</wicri:regionArea>
<placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Cologne</region>
<settlement type="city">Bonn</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ben Ari, Ziv" sort="Ben Ari, Ziv" uniqKey="Ben Ari Z" first="Ziv" last="Ben-Ari">Ziv Ben-Ari</name>
<affiliation wicri:level="1"><nlm:affiliation>Sheba Medical Center, Ramat Gan, Israel.</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Sheba Medical Center, Ramat Gan</wicri:regionArea>
<wicri:noRegion>Ramat Gan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Strasser, Simone I" sort="Strasser, Simone I" uniqKey="Strasser S" first="Simone I" last="Strasser">Simone I. Strasser</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>University of Sydney, Sydney, NSW</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lee, William M" sort="Lee, William M" uniqKey="Lee W" first="William M" last="Lee">William M. Lee</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Texas Southwestern Medical Center, Dallas, TX.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>University of Texas Southwestern Medical Center, Dallas</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Morgan, Leslie" sort="Morgan, Leslie" uniqKey="Morgan L" first="Leslie" last="Morgan">Leslie Morgan</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Qiu, Jingjun" sort="Qiu, Jingjun" uniqKey="Qiu J" first="Jingjun" last="Qiu">Jingjun Qiu</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hwang, Peggy" sort="Hwang, Peggy" uniqKey="Hwang P" first="Peggy" last="Hwang">Peggy Hwang</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Robertson, Michael" sort="Robertson, Michael" uniqKey="Robertson M" first="Michael" last="Robertson">Michael Robertson</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Nguyen, Bach Yen" sort="Nguyen, Bach Yen" uniqKey="Nguyen B" first="Bach-Yen" last="Nguyen">Bach-Yen Nguyen</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Barr, Eliav" sort="Barr, Eliav" uniqKey="Barr E" first="Eliav" last="Barr">Eliav Barr</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Wahl, Janice" sort="Wahl, Janice" uniqKey="Wahl J" first="Janice" last="Wahl">Janice Wahl</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Haber, Barbara" sort="Haber, Barbara" uniqKey="Haber B" first="Barbara" last="Haber">Barbara Haber</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Chase, Robert" sort="Chase, Robert" uniqKey="Chase R" first="Robert" last="Chase">Robert Chase</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Talwani, Rohit" sort="Talwani, Rohit" uniqKey="Talwani R" first="Rohit" last="Talwani">Rohit Talwani</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Marco, Vito Di" sort="Marco, Vito Di" uniqKey="Marco V" first="Vito Di" last="Marco">Vito Di Marco</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Palermo, Palermo, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>University of Palermo, Palermo</wicri:regionArea>
<wicri:noRegion>Palermo</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28256747</idno>
<idno type="pmid">28256747</idno>
<idno type="doi">10.1002/hep.29139</idno>
<idno type="wicri:Area/PubMed/Corpus">000665</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000665</idno>
<idno type="wicri:Area/PubMed/Curation">000663</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000663</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000663</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000663</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.</title>
<author><name sortKey="Hezode, Christophe" sort="Hezode, Christophe" uniqKey="Hezode C" first="Christophe" last="Hézode">Christophe Hézode</name>
<affiliation wicri:level="3"><nlm:affiliation>Henri Mondor Hospital, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Henri Mondor Hospital, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Colombo, Massimo" sort="Colombo, Massimo" uniqKey="Colombo M" first="Massimo" last="Colombo">Massimo Colombo</name>
<affiliation wicri:level="1"><nlm:affiliation>Humanitas Clinical and Research Center, Rozzano, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Humanitas Clinical and Research Center, Rozzano</wicri:regionArea>
<wicri:noRegion>Rozzano</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bourliere, Marc" sort="Bourliere, Marc" uniqKey="Bourliere M" first="Marc" last="Bourlière">Marc Bourlière</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint Joseph, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Saint Joseph, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Spengler, Ulrich" sort="Spengler, Ulrich" uniqKey="Spengler U" first="Ulrich" last="Spengler">Ulrich Spengler</name>
<affiliation wicri:level="3"><nlm:affiliation>University Hospital Bonn, Bonn, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>University Hospital Bonn, Bonn</wicri:regionArea>
<placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Cologne</region>
<settlement type="city">Bonn</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ben Ari, Ziv" sort="Ben Ari, Ziv" uniqKey="Ben Ari Z" first="Ziv" last="Ben-Ari">Ziv Ben-Ari</name>
<affiliation wicri:level="1"><nlm:affiliation>Sheba Medical Center, Ramat Gan, Israel.</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Sheba Medical Center, Ramat Gan</wicri:regionArea>
<wicri:noRegion>Ramat Gan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Strasser, Simone I" sort="Strasser, Simone I" uniqKey="Strasser S" first="Simone I" last="Strasser">Simone I. Strasser</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Sydney, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>University of Sydney, Sydney, NSW</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lee, William M" sort="Lee, William M" uniqKey="Lee W" first="William M" last="Lee">William M. Lee</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Texas Southwestern Medical Center, Dallas, TX.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>University of Texas Southwestern Medical Center, Dallas</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Morgan, Leslie" sort="Morgan, Leslie" uniqKey="Morgan L" first="Leslie" last="Morgan">Leslie Morgan</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Qiu, Jingjun" sort="Qiu, Jingjun" uniqKey="Qiu J" first="Jingjun" last="Qiu">Jingjun Qiu</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hwang, Peggy" sort="Hwang, Peggy" uniqKey="Hwang P" first="Peggy" last="Hwang">Peggy Hwang</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Robertson, Michael" sort="Robertson, Michael" uniqKey="Robertson M" first="Michael" last="Robertson">Michael Robertson</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Nguyen, Bach Yen" sort="Nguyen, Bach Yen" uniqKey="Nguyen B" first="Bach-Yen" last="Nguyen">Bach-Yen Nguyen</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Barr, Eliav" sort="Barr, Eliav" uniqKey="Barr E" first="Eliav" last="Barr">Eliav Barr</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Wahl, Janice" sort="Wahl, Janice" uniqKey="Wahl J" first="Janice" last="Wahl">Janice Wahl</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Haber, Barbara" sort="Haber, Barbara" uniqKey="Haber B" first="Barbara" last="Haber">Barbara Haber</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Chase, Robert" sort="Chase, Robert" uniqKey="Chase R" first="Robert" last="Chase">Robert Chase</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Talwani, Rohit" sort="Talwani, Rohit" uniqKey="Talwani R" first="Rohit" last="Talwani">Rohit Talwani</name>
<affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc, Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Merck & Co., Inc, Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Marco, Vito Di" sort="Marco, Vito Di" uniqKey="Marco V" first="Vito Di" last="Marco">Vito Di Marco</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Palermo, Palermo, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>University of Palermo, Palermo</wicri:regionArea>
<wicri:noRegion>Palermo</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Hepatology (Baltimore, Md.)</title>
<idno type="eISSN">1527-3350</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Benzofurans (administration & dosage)</term>
<term>Biopsy, Needle</term>
<term>Blood Coagulation Disorders, Inherited (complications)</term>
<term>Blood Coagulation Disorders, Inherited (diagnosis)</term>
<term>Blood Coagulation Disorders, Inherited (drug therapy)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Hepacivirus (drug effects)</term>
<term>Hepatitis C, Chronic (complications)</term>
<term>Hepatitis C, Chronic (diagnosis)</term>
<term>Hepatitis C, Chronic (drug therapy)</term>
<term>Humans</term>
<term>Imidazoles (administration & dosage)</term>
<term>Immunohistochemistry</term>
<term>Liver Function Tests</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Quinoxalines (administration & dosage)</term>
<term>Reference Values</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Association de médicaments</term>
<term>Benzofuranes (administration et posologie)</term>
<term>Calendrier d'administration des médicaments</term>
<term>Femelle</term>
<term>Hepacivirus ()</term>
<term>Humains</term>
<term>Hépatite C chronique ()</term>
<term>Hépatite C chronique (diagnostic)</term>
<term>Hépatite C chronique (traitement médicamenteux)</term>
<term>Imidazoles (administration et posologie)</term>
<term>Immunohistochimie</term>
<term>Indice de gravité médicale</term>
<term>Mâle</term>
<term>Ponction-biopsie à l'aiguille</term>
<term>Quinoxalines (administration et posologie)</term>
<term>Relation dose-effet des médicaments</term>
<term>Résultat thérapeutique</term>
<term>Tests de la fonction hépatique</term>
<term>Troubles héréditaires de la coagulation sanguine ()</term>
<term>Troubles héréditaires de la coagulation sanguine (diagnostic)</term>
<term>Troubles héréditaires de la coagulation sanguine (traitement médicamenteux)</term>
<term>Valeurs de référence</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Benzofurans</term>
<term>Imidazoles</term>
<term>Quinoxalines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Benzofuranes</term>
<term>Imidazoles</term>
<term>Quinoxalines</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Blood Coagulation Disorders, Inherited</term>
<term>Hepatitis C, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Blood Coagulation Disorders, Inherited</term>
<term>Hepatitis C, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Hépatite C chronique</term>
<term>Troubles héréditaires de la coagulation sanguine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Hepacivirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Blood Coagulation Disorders, Inherited</term>
<term>Hepatitis C, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite C chronique</term>
<term>Troubles héréditaires de la coagulation sanguine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Biopsy, Needle</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Immunohistochemistry</term>
<term>Liver Function Tests</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Reference Values</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Association de médicaments</term>
<term>Calendrier d'administration des médicaments</term>
<term>Femelle</term>
<term>Hepacivirus</term>
<term>Humains</term>
<term>Hépatite C chronique</term>
<term>Immunohistochimie</term>
<term>Indice de gravité médicale</term>
<term>Mâle</term>
<term>Ponction-biopsie à l'aiguille</term>
<term>Relation dose-effet des médicaments</term>
<term>Résultat thérapeutique</term>
<term>Tests de la fonction hépatique</term>
<term>Troubles héréditaires de la coagulation sanguine</term>
<term>Valeurs de référence</term>
<term>Études de suivi</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Direct-acting antiviral agents have not been studied exclusively in patients with inherited blood disorders and hepatitis C virus (HCV) infection. The objective of the randomized, placebo-controlled, phase III C-EDGE IBLD study was to assess the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) in patients with inherited bleeding disorders and HCV infection. One hundred fifty-nine adults with HCV infection and sickle cell anemia, thalassemia, or hemophilia A/B or von Willebrand disease were enrolled at 31 study sites in the United States, Europe, Australia, Canada, Israel, and Thailand. Patients were given an oral, once-daily, fixed-dose combination of EBR/GZR 50 mg/100 mg for 12 weeks and randomized to the immediate-treatment group (ITG) or deferred-treatment group (DTG; placebo followed by active treatment). The primary endpoints were the proportion of patients in the ITG with unquantifiable HCV RNA 12 weeks posttreatment (sustained virological response 12 weeks after completion of study treatment; SVR12) and the comparison of safety in the ITG and DTG. In the ITG, 100 of 107 patients (93.5%) achieved SVR12, 6 relapsed, and 1 was lost to follow-up. SVR12 was achieved in 94.7% (18 of 19), 97.6% (40 of 41), and 89.4% (42 of 47) of patients with sickle cell disease, β-thalassemia, and hemophilia A/B or von Willebrand disease, respectively. Serious adverse events were reported by 2.8% (n = 3) and 11.5% (n = 6) of patients in the ITG and DTG, respectively. Hemoglobin levels and international normalized ratio values were similar in patients receiving EBR/GZR and placebo; among patients with hemoglobinopathies, change in mean hemoglobin levels was similar in those receiving EBR/GZR compared to those receiving placebo.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28256747</PMID>
<DateCreated><Year>2017</Year>
<Month>03</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted><Year>2017</Year>
<Month>10</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>10</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3350</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>66</Volume>
<Issue>3</Issue>
<PubDate><Year>2017</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Hepatology (Baltimore, Md.)</Title>
<ISOAbbreviation>Hepatology</ISOAbbreviation>
</Journal>
<ArticleTitle>Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.</ArticleTitle>
<Pagination><MedlinePgn>736-745</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.29139</ELocationID>
<Abstract><AbstractText>Direct-acting antiviral agents have not been studied exclusively in patients with inherited blood disorders and hepatitis C virus (HCV) infection. The objective of the randomized, placebo-controlled, phase III C-EDGE IBLD study was to assess the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) in patients with inherited bleeding disorders and HCV infection. One hundred fifty-nine adults with HCV infection and sickle cell anemia, thalassemia, or hemophilia A/B or von Willebrand disease were enrolled at 31 study sites in the United States, Europe, Australia, Canada, Israel, and Thailand. Patients were given an oral, once-daily, fixed-dose combination of EBR/GZR 50 mg/100 mg for 12 weeks and randomized to the immediate-treatment group (ITG) or deferred-treatment group (DTG; placebo followed by active treatment). The primary endpoints were the proportion of patients in the ITG with unquantifiable HCV RNA 12 weeks posttreatment (sustained virological response 12 weeks after completion of study treatment; SVR12) and the comparison of safety in the ITG and DTG. In the ITG, 100 of 107 patients (93.5%) achieved SVR12, 6 relapsed, and 1 was lost to follow-up. SVR12 was achieved in 94.7% (18 of 19), 97.6% (40 of 41), and 89.4% (42 of 47) of patients with sickle cell disease, β-thalassemia, and hemophilia A/B or von Willebrand disease, respectively. Serious adverse events were reported by 2.8% (n = 3) and 11.5% (n = 6) of patients in the ITG and DTG, respectively. Hemoglobin levels and international normalized ratio values were similar in patients receiving EBR/GZR and placebo; among patients with hemoglobinopathies, change in mean hemoglobin levels was similar in those receiving EBR/GZR compared to those receiving placebo.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results add to the expanding pool of data available for EBR/GZR, indicating a high level of efficacy and favorable tolerability in patients with HCV infection. (Hepatology 2017;66:736-745).</AbstractText>
<CopyrightInformation>© 2017 by the American Association for the Study of Liver Diseases.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hézode</LastName>
<ForeName>Christophe</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Henri Mondor Hospital, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Colombo</LastName>
<ForeName>Massimo</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Humanitas Clinical and Research Center, Rozzano, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bourlière</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Hôpital Saint Joseph, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Spengler</LastName>
<ForeName>Ulrich</ForeName>
<Initials>U</Initials>
<AffiliationInfo><Affiliation>University Hospital Bonn, Bonn, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ben-Ari</LastName>
<ForeName>Ziv</ForeName>
<Initials>Z</Initials>
<AffiliationInfo><Affiliation>Sheba Medical Center, Ramat Gan, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Strasser</LastName>
<ForeName>Simone I</ForeName>
<Initials>SI</Initials>
<AffiliationInfo><Affiliation>University of Sydney, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>William M</ForeName>
<Initials>WM</Initials>
<AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Morgan</LastName>
<ForeName>Leslie</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Merck & Co., Inc, Kenilworth, NJ.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Qiu</LastName>
<ForeName>Jingjun</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Merck & Co., Inc, Kenilworth, NJ.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hwang</LastName>
<ForeName>Peggy</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Merck & Co., Inc, Kenilworth, NJ.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Robertson</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Merck & Co., Inc, Kenilworth, NJ.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nguyen</LastName>
<ForeName>Bach-Yen</ForeName>
<Initials>BY</Initials>
<AffiliationInfo><Affiliation>Merck & Co., Inc, Kenilworth, NJ.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Barr</LastName>
<ForeName>Eliav</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Merck & Co., Inc, Kenilworth, NJ.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wahl</LastName>
<ForeName>Janice</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Merck & Co., Inc, Kenilworth, NJ.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Haber</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Merck & Co., Inc, Kenilworth, NJ.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chase</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Merck & Co., Inc, Kenilworth, NJ.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Talwani</LastName>
<ForeName>Rohit</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Merck & Co., Inc, Kenilworth, NJ.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Marco</LastName>
<ForeName>Vito Di</ForeName>
<Initials>VD</Initials>
<AffiliationInfo><Affiliation>University of Palermo, Palermo, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>C-EDGE IBLD Study Investigators</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>07</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Hepatology</MedlineTA>
<NlmUniqueID>8302946</NlmUniqueID>
<ISSNLinking>0270-9139</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8YE81R1X1J</RegistryNumber>
<NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001707" MajorTopicYN="N">Biopsy, Needle</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D025861" MajorTopicYN="N">Blood Coagulation Disorders, Inherited</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008111" MajorTopicYN="N">Liver Function Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>11</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2017</Year>
<Month>01</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>02</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>3</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>10</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>3</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28256747</ArticleId>
<ArticleId IdType="doi">10.1002/hep.29139</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>France</li>
<li>Israël</li>
<li>Italie</li>
<li>États-Unis</li>
</country>
<region><li>District de Cologne</li>
<li>New Jersey</li>
<li>Nouvelle-Galles du Sud</li>
<li>Provence-Alpes-Côte d'Azur</li>
<li>Rhénanie-du-Nord-Westphalie</li>
<li>Texas</li>
<li>Île-de-France</li>
</region>
<settlement><li>Bonn</li>
<li>Marseille</li>
<li>Paris</li>
<li>Sydney</li>
</settlement>
<orgName><li>Université de Sydney</li>
</orgName>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Hezode, Christophe" sort="Hezode, Christophe" uniqKey="Hezode C" first="Christophe" last="Hézode">Christophe Hézode</name>
</region>
<name sortKey="Bourliere, Marc" sort="Bourliere, Marc" uniqKey="Bourliere M" first="Marc" last="Bourlière">Marc Bourlière</name>
</country>
<country name="Italie"><noRegion><name sortKey="Colombo, Massimo" sort="Colombo, Massimo" uniqKey="Colombo M" first="Massimo" last="Colombo">Massimo Colombo</name>
</noRegion>
<name sortKey="Marco, Vito Di" sort="Marco, Vito Di" uniqKey="Marco V" first="Vito Di" last="Marco">Vito Di Marco</name>
</country>
<country name="Allemagne"><region name="Rhénanie-du-Nord-Westphalie"><name sortKey="Spengler, Ulrich" sort="Spengler, Ulrich" uniqKey="Spengler U" first="Ulrich" last="Spengler">Ulrich Spengler</name>
</region>
</country>
<country name="Israël"><noRegion><name sortKey="Ben Ari, Ziv" sort="Ben Ari, Ziv" uniqKey="Ben Ari Z" first="Ziv" last="Ben-Ari">Ziv Ben-Ari</name>
</noRegion>
</country>
<country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Strasser, Simone I" sort="Strasser, Simone I" uniqKey="Strasser S" first="Simone I" last="Strasser">Simone I. Strasser</name>
</region>
</country>
<country name="États-Unis"><region name="Texas"><name sortKey="Lee, William M" sort="Lee, William M" uniqKey="Lee W" first="William M" last="Lee">William M. Lee</name>
</region>
<name sortKey="Barr, Eliav" sort="Barr, Eliav" uniqKey="Barr E" first="Eliav" last="Barr">Eliav Barr</name>
<name sortKey="Chase, Robert" sort="Chase, Robert" uniqKey="Chase R" first="Robert" last="Chase">Robert Chase</name>
<name sortKey="Haber, Barbara" sort="Haber, Barbara" uniqKey="Haber B" first="Barbara" last="Haber">Barbara Haber</name>
<name sortKey="Hwang, Peggy" sort="Hwang, Peggy" uniqKey="Hwang P" first="Peggy" last="Hwang">Peggy Hwang</name>
<name sortKey="Morgan, Leslie" sort="Morgan, Leslie" uniqKey="Morgan L" first="Leslie" last="Morgan">Leslie Morgan</name>
<name sortKey="Nguyen, Bach Yen" sort="Nguyen, Bach Yen" uniqKey="Nguyen B" first="Bach-Yen" last="Nguyen">Bach-Yen Nguyen</name>
<name sortKey="Qiu, Jingjun" sort="Qiu, Jingjun" uniqKey="Qiu J" first="Jingjun" last="Qiu">Jingjun Qiu</name>
<name sortKey="Robertson, Michael" sort="Robertson, Michael" uniqKey="Robertson M" first="Michael" last="Robertson">Michael Robertson</name>
<name sortKey="Talwani, Rohit" sort="Talwani, Rohit" uniqKey="Talwani R" first="Rohit" last="Talwani">Rohit Talwani</name>
<name sortKey="Wahl, Janice" sort="Wahl, Janice" uniqKey="Wahl J" first="Janice" last="Wahl">Janice Wahl</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D42 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000D42 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:28256747
   |texte=   Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:28256747" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.

Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki